유세포 분석 시장 - 세계 및 지역별 분석 : 제공 유형별, 방법별, 용도별, 최종사용자별, 지역별 - 분석과 예측(2025-2035년)

This report can be delivered within 1 working day.

Introduction of Flow Cytometry Market

The global flow cytometry market, valued at $3,392.5 million in 2024, is on a robust growth trajectory and is anticipated to reach $7,371.9 million by 2035. This market is expected to expand at a compound annual growth rate (CAGR) of 7.40% between 2025 and 2035. Flow cytometry plays a crucial role in clinical diagnostics, drug development, and research applications, with its ability to analyze and sort cells based on multiple parameters.

Market Introduction

Flow cytometry is a powerful analytical technology enabling multiparametric analysis of individual cells in suspension, widely used in research, clinical diagnostics, and biopharmaceutical development. Its applications span immunophenotyping, cell cycle analysis, and biomarker detection, driving demand across oncology, immunology, and infectious disease research. With advancements in spectral flow cytometry and high-throughput systems, the market is poised for significant growth, supported by increasing adoption in personalized medicine and cell therapy, and the expanding use of sophisticated reagents and software for precise cell analysis.

Regional Segmentation:

• North America
  • U.S.
  • Canada
• Europe
  • U.K.
  • Germany
  • France
  • Italy
  • Spain
  • Rest-of-Erope
• Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Thailand
  • Singapore
  • Rest-of-Asia-Pacific
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Rest-of-Latin America
• Middle East & Africa

The regional analysis of the flow cytometry market reveals a diversified landscape, with North America leading in market share, followed by Europe, Asia-Pacific, Latin America, and the Middle East & Africa. North America, with a market value of $1,497.1 million in 2024, is anticipated to maintain its dominance throughout the forecast period, driven by factors such as advanced healthcare infrastructure, rapid adoption of cutting-edge research tools, favorable reimbursement policies in clinical diagnostics., and increasing prevalence of cancer. Europe, with a market value of $928.3 million in 2024, is expected to witness steady growth propelled by strong research infrastructure, established biotech hubs (Germany, the U.K., France, and the Netherlands), and the increasing clinical utility in hematology and immunology.. Asia-Pacific is expected to emerge as the fastest-growing region with a CAGR of 9.04% from 2025 to 2035, fueled by significant advancements in life sciences research, increasing healthcare investments, and a growing demand for precision diagnostics. Latin America and the Middle East & Africa regions are also expected to show promising growth opportunities, driven by improving healthcare infrastructure and a rising investments in life sciences research. This regional analysis underscores the global scope and potential of the flow cytometry market, with each region contributing uniquely to its overall growth trajectory.

Recent Developments in the Flow Cytometry Market

• In May 2025, Cytek Biosciences launched the Cytek Aurora Evo, an advanced full-spectrum flow cytometer that builds upon the capabilities of its flagship Aurora system.
• In May 2025, Becton, Dickinson and Company launched the world's first cell analyzer combining advanced spectral and real-time cell imaging technologies. This innovation enables researchers to gain deeper cellular insights across more applications, with enhanced ease and higher throughput in flow cytometry.
• In March 2025, Beckman Coulter Life Sciences, a Danaher company, introduced the CytoFLEX mosaic Spectral Detection Module-the industry's first modular solution transforming spectral flow cytometry.
• In February 2025, Becton, Dickinson and Company announced plans to spin off its Biosciences and Diagnostic Solutions business to sharpen strategic focus and enhance shareholder value. Post-separation, "New BD" will be a pure-play MedTech company focused on innovation, growth, and targeted investments, while the spun-off unit will operate as a standalone life sciences leader.
• In January 2025, Bio-Rad Laboratories launched its TrailBlazer Tag and StarBright Dye Label Kits, providing an easy way to label antibodies for flow cytometry and fluorescent western blot applications.

How can this report add value to an organization?

Product/Innovation Strategy: The flow cytometry market analysis provides insights into evolving research and clinical needs, enabling organizations to develop customized flow cytometry instruments, reagents, and software solutions that address specific requirements such as high-parameter analysis, spectral capabilities, or streamlined workflows for clinical diagnostics.

Growth/Marketing Strategy: The report helps organizations implement targeted marketing strategies tailored to key segments such as academic research, immuno-oncology, or infectious disease diagnostics and specific regional opportunities, improving customer engagement and accelerating adoption.

Competitive Strategy: Organizations can differentiate their flow cytometry offerings by emphasizing features particularly valued by end-users in target regions, such as instrument scalability, ease of use, reagent compatibility, after-sales support, or specialized applications like cell therapy or immunophenotyping.

Methodology

Key Considerations and Assumptions in Market Engineering and Validation

• The base year considered for the calculation of the market size is 2024. A historical year analysis has been done for the period FY2021-FY2023. The market size has been estimated for FY2024 and projected for the period FY2025-FY2035.
• The scope of this report has been carefully derived based on interactions with experts in different companies worldwide.
• The market contribution of flow cytometry anticipated to be launched in the future has been calculated based on the historical analysis of the solutions.
• Revenues of the companies have been referenced from their annual reports for FY2023 and FY2024. For private companies, revenues have been estimated based on factors such as inputs obtained from primary research, funding history, market collaborations, and operational history.
• The market has been mapped based on the available flow cytometry products. This report has considered and profiled all the key companies with significant offerings in this field.
• The report excludes repair and maintenance services, other flow cytometry-related services, and refurbished instruments from the market sizing and forecast analysis, focusing purely on new product sales and innovations.

Primary Research:

The primary sources involve industry experts in flow cytometry, including the market players offering products and services. Resources such as CEOs, vice presidents, marketing directors, and salespersons have been interviewed to obtain and verify both qualitative and quantitative aspects of this research study.

The key data points taken from the primary sources include:

• Validation and triangulation of all the numbers and graphs
• Validation of the report's segmentation and key qualitative findings
• Understanding the competitive landscape and business model
• Current and proposed production values of a product by market players
• Percentage split of individual markets for regional analysis

Secondary Research

Open Sources

• Certified publications, articles from recognized authors, white papers, directories, and major databases, among others
• Annual reports, SEC filings, and investor presentations of the leading market players
• Company websites and detailed study of their product portfolio
• Gold standard magazines, journals, white papers, press releases, and news articles
• Paid databases

The key data points taken from the secondary sources include:

• Segmentations and percentage shares
• Data for market value
• Key industry trends of the top players of the market
• Qualitative insights into various aspects of the market, key trends, and emerging areas of innovation
• Quantitative data for mathematical and statistical calculations

Key Market Players and Competition Synopsis

The global flow cytometry market is dominated by Becton, Dickinson and Company, Danaher Corporation (Beckman Coulter, Inc.), and Thermo Fisher Scientific Inc., each offering comprehensive portfolios of instruments, reagents, and consumables that set industry benchmarks for clinical diagnostics and advanced biomedical research. Bio-Rad Laboratories, Inc. specializes in high-resolution flow cytometry solutions and innovative reagents, solidifying its position as a key player in immune research and oncology diagnostics. Cytek Biosciences, Inc., with its cost-effective, high-parameter systems like the Cytek Aurora, is rapidly capturing market share, particularly in advanced spectral applications, and emerging as a formidable competitor. Regional players such as Agilent Technologies, Inc. and Sony Biotechnology, Inc. continue to innovate in specialized niches, including spectral flow cytometry and customized cell analysis tools. To sustain growth, market leaders must focus on continuous product innovation, expanding reagent portfolios, and forging strategic collaborations to address the evolving needs of precision medicine and personalized diagnostics.

Some prominent names established in flow cytometry market are:

Becton, Dickinson and Company (BD)

Danaher Corporation (Beckman Coulter, Inc.)

Thermo Fisher Scientific Inc.

Bio-Rad Laboratories, Inc.

Cytek Biosciences

Agilent Technologies, Inc.

Sony Biotechnology, Inc.

Table of Contents

Executive Summary

Scope and Definition

1 Market: Industry Outlook

• 1.1 Global Flow Cytometry Market, Market Size (US$), 2024-2035
  • 1.1.1 Overview
  • 1.1.2 Key Findings
• 1.2 Regulatory Landscape/Compliance
  • 1.2.1 U.S.
  • 1.2.2 Europe
  • 1.2.3 Japan
  • 1.2.4 Rest-of-the-World

2 Market: Industry Outlook

• 2.1 Market Dynamics
  • 2.1.1 Trends, Drivers, Challenges, and Opportunities: Current and Future Impact Assessment, 2024-2035
• 2.2 Trends
  • 2.2.1 Continuous Technological Innovations in Flow Cytometry
  • 2.2.2 Increasing Collaborations, Strategic Partnerships, and Alliances among Flow Cytometry Players
• 2.3 Market Dynamics
  • 2.3.1 Market Drivers
    • 2.3.1.1 Rising Cancer Prevalence and the Growing Demand for Advanced Diagnostic Testing
    • 2.3.1.2 Growing Use of Flow Cytometry in Regenerative Medicine
    • 2.3.1.3 Growing Healthcare R&D Spending Fuels Adoption of Flow Cytometry Technologies
  • 2.3.2 Market Restraints
    • 2.3.2.1 High Cost of Acquisition
  • 2.3.3 Market Opportunities
    • 2.3.3.1 Increased Use in Clinical Applications and Infectious Disease Diagnostics

3 Offering Type

• 3.1 Offering Type Summary
• 3.2 Growth-Share Matrix
  • 3.2.1 Instruments
    • 3.2.1.1 Platforms
      • 3.2.1.1.1 Conventional Flow Cytometers (Non-Sorting)
      • 3.2.1.1.2 Fluorescence Activated Cell Sorting (FACS)
      • 3.2.1.1.3 Imaging Flow Cytometers
      • 3.2.1.1.4 Spectral Flow Cytometers
      • 3.2.1.1.5 Others
    • 3.2.1.2 Replaceable Components and Accessories
  • 3.2.2 Reagents and Consumables
    • 3.2.2.1 Antibodies
    • 3.2.2.2 Fluorescent Dye
    • 3.2.2.3 Beads
    • 3.2.2.4 Others
  • 3.2.3 Software

4 Method

• 4.1 Method Summary
• 4.2 Growth-Share Matrix
  • 4.2.1 Cell-Based Flow Cytometry
  • 4.2.2 Bead-Based Flow Cytometry

5 Application

• 5.1 Application Summary
• 5.2 Growth-Share Matrix
  • 5.2.1 Clinical Application
    • 5.2.1.1 Cancer (Solid Tumor)
    • 5.2.1.2 Hematology
    • 5.2.1.3 Autoimmune Diseases
    • 5.2.1.4 Organ Transplantation
    • 5.2.1.5 Others
  • 5.2.2 Research Application
    • 5.2.2.1 Drug Discovery
    • 5.2.2.2 Biomarker Detection
    • 5.2.2.3 In-Vitro Toxicology Testing
    • 5.2.2.4 Stem Cell Research
    • 5.2.2.5 Cell Cycle Analysis
    • 5.2.2.6 Cell Viability
    • 5.2.2.7 Cell Apoptosis
    • 5.2.2.8 Others
  • 5.2.3 Industrial
    • 5.2.3.1 Food and Beverages
    • 5.2.3.2 Water Treatment
    • 5.2.3.3 Microbiology Testing
    • 5.2.3.4 Cosmetics and Personal Care Industry
    • 5.2.3.5 Agriculture and Fermentation Industry
    • 5.2.3.6 Other Industries

6 End User

• 6.1 End User Summary
• 6.2 Growth-Share Matrix
  • 6.2.1 Pharmaceutical and Biotechnology Companies
  • 6.2.2 Hospitals and Clinical Testing Laboratories
  • 6.2.3 Academic and Research Institutes
  • 6.2.4 Other Industries

7 Region

• 7.1 Regional Summary
• 7.2 Growth-Share Matrix
  • 7.2.1 North America
    • 7.2.1.1 Regional Overview
    • 7.2.1.2 Driving Factors for Market Growth
    • 7.2.1.3 Factors Challenging the Market
    • 7.2.1.4 Funding Initiatives & Grants
    • 7.2.1.5 By Country
      • 7.2.1.5.1 U.S.
      • 7.2.1.5.2 Canada
  • 7.2.2 Europe
    • 7.2.2.1 Regional Overview
    • 7.2.2.2 Driving Factors for Market Growth
    • 7.2.2.3 Factors Challenging the Market
    • 7.2.2.4 Funding Initiatives and Grants
    • 7.2.2.5 By Country
    • 7.2.2.6 U.K.
    • 7.2.2.7 Germany
    • 7.2.2.8 France
    • 7.2.2.9 Italy
    • 7.2.2.10 Spain
    • 7.2.2.11 Rest-of-Europe
  • 7.2.3 Asia-Pacific
    • 7.2.3.1 Regional Overview
    • 7.2.3.2 Driving Factors for Market Growth
    • 7.2.3.3 Factors Challenging the Market
    • 7.2.3.4 By Country
    • 7.2.3.5 China
    • 7.2.3.6 Japan
    • 7.2.3.7 India
    • 7.2.3.8 South Korea
    • 7.2.3.9 Australia
    • 7.2.3.10 Thailand
    • 7.2.3.11 Singapore
    • 7.2.3.12 Rest-of-the-Asia-Pacific
  • 7.2.4 Latin America
    • 7.2.4.1 Regional Overview
    • 7.2.4.2 Driving Factors for Market Growth
    • 7.2.4.3 Factors Challenging the Market
    • 7.2.4.4 By Country
    • 7.2.4.5 Brazil
    • 7.2.4.6 Mexico
    • 7.2.4.7 Argentina
    • 7.2.4.8 Rest-of-Latin America
  • 7.2.5 Middle East and Africa
    • 7.2.5.1 Regional Overview
    • 7.2.5.2 Driving Factors for Market Growth
    • 7.2.5.3 Factors Challenging the Market

8 Markets - Competitive Benchmarking & Company Profiles

• 8.1 Product Benchmarking By Company
• 8.2 Competitive Landscape
  • 8.2.1 Key Strategies and Developments by Company
    • 8.2.1.1 Product Launch
    • 8.2.1.2 Partnerships
    • 8.2.1.3 Funding, Business Expansion, and Corporate Restructuring
    • 8.2.1.4 Regulatory Activities
    • 8.2.1.5 Merger and Acquisitions
  • 8.2.2 Company Position Analysis in Flow Cytometry Market
  • 8.2.3 Company Share Analysis in Flow Cytometry Market
• 8.3 Company Profiles
  • 8.3.1 Agilent Technologies, Inc.
    • 8.3.1.1 Overview
    • 8.3.1.2 Top Products/Product Portfolio
    • 8.3.1.3 Top Competitors
    • 8.3.1.4 Key Strategic Developments
    • 8.3.1.5 Analyst View
    • 8.3.1.6 Financial Analysis
  • 8.3.2 Becton, Dickinson and Company
    • 8.3.2.1 Overview
    • 8.3.2.2 Top Products/Product Portfolio
    • 8.3.2.3 Top Competitors
    • 8.3.2.4 Key Strategic Developments
    • 8.3.2.5 Analyst View
    • 8.3.2.6 Financial Analysis
  • 8.3.3 Bio-Rad Laboratories, Inc.
    • 8.3.3.1 Overview
    • 8.3.3.2 Top Products/Product Portfolio
    • 8.3.3.3 Top Competitors
    • 8.3.3.4 Key Strategic Developments
    • 8.3.3.5 Analyst View
    • 8.3.3.6 Financial Analysis
  • 8.3.4 Cytek Biosciences, Inc.
    • 8.3.4.1 Overview
    • 8.3.4.2 Top Products/Product Portfolio
    • 8.3.4.3 Top Competitors
    • 8.3.4.4 Key Strategic Developments
    • 8.3.4.5 Analyst View
    • 8.3.4.6 Key Personal
  • 8.3.5 Danaher Corporation (Beckman Coulter)
    • 8.3.5.1 Overview
    • 8.3.5.2 Top Products/Product Portfolio
    • 8.3.5.3 Top Competitors
    • 8.3.5.4 Key Strategic Developments
    • 8.3.5.5 Analyst View
    • 8.3.5.6 Financial Analysis
  • 8.3.6 Sony Biotechnology Inc.
    • 8.3.6.1 Overview
    • 8.3.6.2 Top Products/Product Portfolio
    • 8.3.6.3 Top Competitors
    • 8.3.6.4 Key Strategic Developments
    • 8.3.6.5 Analyst View
  • 8.3.7 Thermo Fisher Scientific Inc.
    • 8.3.7.1 Overview
    • 8.3.7.2 Top Products/Product Portfolio
    • 8.3.7.3 Top Competitors
    • 8.3.7.4 Key Strategic Developments
    • 8.3.7.5 Analyst View
    • 8.3.7.6 Financial Analysis
  • 8.3.8 Sysmex Corporation
    • 8.3.8.1 Overview
    • 8.3.8.2 Top Products/Product Portfolio
    • 8.3.8.3 Top Competitors
    • 8.3.8.4 Key Strategic Developments
    • 8.3.8.5 Analyst View
    • 8.3.8.6 Financial Analysis
  • 8.3.9 Merck KGaA
    • 8.3.9.1 Overview
    • 8.3.9.2 Top Products/Product Portfolio
    • 8.3.9.3 Top Competitors
    • 8.3.9.4 Target Customers
    • 8.3.9.5 Key Personal
    • 8.3.9.6 Analyst View
    • 8.3.9.7 Financial Analysis
  • 8.3.10 Miltenyi Biotec
    • 8.3.10.1 Overview
    • 8.3.10.2 Top Products/Product Portfolio
    • 8.3.10.3 Top Competitors
    • 8.3.10.4 Target Customers
    • 8.3.10.5 Key Personal
    • 8.3.10.6 Analyst View
    • 8.3.10.7 Financial Analysis
  • 8.3.11 Stratedigm, Inc.
    • 8.3.11.1 Overview
    • 8.3.11.2 Top Products/Product Portfolio
    • 8.3.11.3 Top Competitors
    • 8.3.11.4 Target Customers
    • 8.3.11.5 Key Personal
    • 8.3.11.6 Analyst View
  • 8.3.12 Cell Signaling Technology Inc.
    • 8.3.12.1 Overview
    • 8.3.12.2 Top Products/Product Portfolio
    • 8.3.12.3 Top Competitors
    • 8.3.12.4 Target Customers
    • 8.3.12.5 Key Personal
    • 8.3.12.6 Analyst View
  • 8.3.13 STEMCELL Technologies
    • 8.3.13.1 Overview
    • 8.3.13.2 Top Products/Product Portfolio
    • 8.3.13.3 Top Competitors
    • 8.3.13.4 Target Customers
    • 8.3.13.5 Key Personal
    • 8.3.13.6 Analyst View
  • 8.3.14 Bio-Techne
    • 8.3.14.1 Overview
    • 8.3.14.2 Top Products/Product Portfolio
    • 8.3.14.3 Top Competitors
    • 8.3.14.4 Target Customers
    • 8.3.14.5 Key Personal
    • 8.3.14.6 Analyst View
    • 8.3.14.7 Financial Analysis
  • 8.3.15 Revvity (BioLegend, Inc)
    • 8.3.15.1 Overview
    • 8.3.15.2 Top Products/Product Portfolio
    • 8.3.15.3 Top Competitors
    • 8.3.15.4 Target Customers
    • 8.3.15.5 Key Personal
    • 8.3.15.6 Analyst View
    • 8.3.15.7 Financial Analysis

9 Research Methodology

• 9.1 Data Sources
  • 9.1.1 Primary Data Sources
  • 9.1.2 Secondary Data Sources
  • 9.1.3 Data Triangulation
• 9.2 Market Estimation and Forecast